Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
Open Access
- 1 January 2016
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (1), 44-51
- https://doi.org/10.1210/jc.2015-1860
Abstract
Context:Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM).Objective:Our objective is to describe the effects of canagliflozin on bone mineral density (BMD) and bone biomarkers in patients with T2DM.Design:This was a randomized study, consisting of a 26-week, double-blind, placebo-controlled period and a 78-week, double-blind, placebo-controlled extension.Setting:This study was undertaken in 90 centers in 17 countries.Patients:Patients were aged 55–80 years (N = 716) and whose T2DM was inadequately controlled on a stable antihyperglycemic regimen.Interventions:Canagliflozin 100 or 300 mg or placebo were administered once daily.Outcome and Measures:BMD was assessed using dual-energy x-ray absorptiometry at weeks 26, 52, and 104. Bone strength was assessed using quantitative computed tomography and finite element analysis at week 52. Serum collagen type 1 β-carboxy-telopeptide, osteocalcin, and estradiol were assessed at weeks 26 and 52.Results:Canagliflozin doses of 100 and 300 mg were associated with a decrease in total hip BMD over 104 weeks, (placebo-subtracted changes: −0.9% and −1.2%, respectively), but not at other sites measured (femoral neck, lumbar spine, or distal forearm). No meaningful changes in bone strength were observed. At week 52, canagliflozin was associated with an increase in collagen type 1 β-carboxy-telopeptide that was significantly correlated with a reduction in body weight, an increase in osteocalcin, and, in women, a decrease in estradiol.Conclusions:In older patients with T2DM, canagliflozin showed small but significant reductions in total hip BMD and increases in bone formation and resorption biomarkers, due at least in part to weight loss.Keywords
This publication has 40 references indexed in Scilit:
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal ModelsPLOS ONE, 2012
- Weight-loss-associated changes in bone mineral density and bone turnover after partial weight regain with or without aerobic exercise in obese womenEuropean Journal of Clinical Nutrition, 2011
- Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin SecretionDiabetes, 2011
- Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trialJournal of Bone and Mineral Research, 2011
- Areal and volumetric bone mineral density and geometry at two levels of protein intake during caloric restriction: A randomized, controlled trialJournal of Bone and Mineral Research, 2010
- Finite Element Analysis of the Proximal Femur and Hip Fracture Risk in Older MenJournal of Bone and Mineral Research, 2009